tradit
antivir
drug
develop
target
specif
enzym
encod
virus
explain
excel
specif
select
mani
drug
also
explain
potent
licens
broad
spectrum
antivir
drug
target
enzym
specif
viru
famili
note
ribavirin
although
broad
spectrum
potent
antivir
drug
cidofovir
licens
treatment
sever
virus
activ
except
virus
two
differ
famili
share
particular
enzym
revers
transcriptas
case
hiv
hbv
drug
lamivudin
activ
virus
spectr
natur
epidem
even
bioterror
demand
explor
differ
approach
rapid
respons
requir
novel
influenza
viru
cross
human
threaten
caus
pandem
rapid
respons
also
requir
whole
host
rare
infect
financi
argument
develop
compound
specif
infecti
agent
would
therefor
possibl
rather
target
infect
target
common
compon
diseas
trigger
differ
virus
way
diseas
would
seen
complic
infect
treatment
would
direct
downstream
pathogenet
effector
mechan
share
virus
distinct
famili
sever
possibl
exampl
present
first
reninangiotensin
system
well
known
contribut
hypertens
also
involv
diffus
alveolar
damag
known
acut
respiratori
distress
syndrom
ard
compon
respiratori
diseas
caus
sar
coronaviru
influenza
virus
angiotensin
convert
enzym
ace
cleav
angiotensin
angiotensin
ii
bind
altern
receptor
lung
either
caus
receptor
decreas
receptor
protein
transud
lung
oedema
tissu
damag
angiotensin
ii
cleav
benign
form
action
receptor
sar
coronaviru
well
benign
recent
describ
coronaviru
recent
report
natur
medicin
show
sar
coronaviru
downregul
probabl
exagger
ard
respons
decreas
inactiv
angiotensin
ii
ace
furthermor
recombin
reduc
lung
injuri
mice
diffus
alveolar
damag
antagonist
receptor
although
remain
unresolv
matter
detail
therapeut
implic
clear
reappear
sar
appear
unlik
immin
arriv
influenza
viru
offer
potenti
evalu
randomis
control
trial
efficaci
alreadi
licens
antihypertens
receptor
inhibitor
andor
recombin
ace
adjuv
therapi
neuraminidas
inhibitor
unfortun
human
becom
infect
second
despit
caus
divers
member
filovirida
arenavirida
flavivirida
bunyavirida
mani
variou
haemorrhag
fever
share
element
pathogenesi
cardiovascular
manifest
hypovolaemia
hypotens
petechia
mucos
haemorrhag
bleed
venepunctur
site
due
blood
loss
variou
combin
dissemin
intravascular
coagul
dic
thrombocytopenia
adren
insuffici
bleed
time
prothrombin
time
activ
partial
thromboplastin
time
frequent
prolong
decreas
synthesi
coagul
factor
within
liver
contribut
caus
multipl
organ
dysfunct
defect
clot
coexist
defect
fibrinolysi
thu
consum
labil
coagul
factor
produc
liver
overexpress
tissu
factor
monocytesmacrophag
anoth
compon
pathogenesi
thrombocytopenia
may
result
interferoninduc
arrest
megakaryocyt
matur
disrupt
function
endotheli
cell
also
suggest
contributor
haemorrhag
diathesi
ebola
viru
glycoprotein
directli
damag
endotheli
cell
howev
current
evid
suggest
endotheli
involv
occur
late
diseas
process
pretermin
event
therapeut
implic
drug
abl
interfer
coagulopathi
induc
haemorrhag
fever
virus
might
broad
clinic
applic
exampl
dic
paradox
treat
human
anticoagul
heparin
ultim
lead
cessat
consumpt
clot
factor
evid
anim
studi
interf
clot
improv
outcom
haemorrhag
fever
human
anecdot
use
heparin
likewis
recombin
nematod
anticoagul
protein
protein
inhibit
tissu
factor
factor
viia
complex
block
clot
improv
surviv
given
macaqu
infect
ebola
viru
third
hepat
b
hbv
hepat
c
hcv
frequent
establish
chronic
infect
lead
decad
cirrhosi
liver
failur
without
hepatocellular
carcinoma
common
compon
pathogenesi
cirrhosi
fibrosi
lead
distort
perman
remodel
liver
architectur
explain
haemodynam
effect
cirrhosi
allow
toxin
absorb
gut
reach
brain
caus
hepat
encephalopathi
fibrosi
defin
wound
maintain
chronic
signal
tissu
repair
tgfi
master
switch
profibrot
gene
shown
studi
radiat
induc
fibrosi
transgen
mice
tgfunder
control
albumin
promot
show
hepatocyt
specif
express
tgfand
produc
extens
hepat
fibrosi
carbon
tetrachlorid
use
liver
toxin
normal
mice
tnf
receptor
knockout
acut
infect
similar
chronic
inflamm
tgflevel
fibrosi
significantli
decreas
knockout
mice
implic
tnfa
also
profibrot
human
transplant
hiv
patient
show
acceler
fibrosi
immun
control
viral
replic
must
decreas
liver
inflamm
howev
immun
may
act
dualedg
sword
studi
intrahepat
tcell
reveal
virusspecif
cell
provid
protect
nonspecif
cell
contribut
inflamm
addit
gene
hcv
genom
link
report
gene
control
tgfpromot
core
protein
produc
activ
evid
mitogen
activ
kinas
pathway
involv
directli
stimul
fibrogenesi
irrespect
tgfi
stimul
fibrosi
similar
stellat
cell
profibrot
activ
transdifferenti
becom
myofibroblast
matrix
metalloproteinas
produc
fibroblast
macrophag
digest
fibrot
extracellular
matrix
inhibit
tissu
inhibitor
metalloproteinas
timp
decreas
inflamm
reduc
timp
thu
allow
activ
stellat
cell
remov
apoptosi
regress
fibrosi
occur
even
cirrhot
liver
ultim
clinic
respons
limit
degre
matrix
cross
link
produc
tissu
transglutaminas
block
function
metalloproteinas
argu
favour
interven
therapeut
soon
fibrosi
identifi
convent
fibrosi
detect
histopatholog
examin
liver
biopsi
quantif
mrna
profibrot
gene
also
evalu
less
invas
serial
biochem
assess
blood
show
improv
abil
identifi
liver
fibrosi
exampl
intern
multicentr
evalu
panel
biomark
measur
variou
element
matrix
synthesi
matrix
degrad
sensit
neg
predict
valu
identifi
fibrosi
liver
biopsi
patient
implic
treatment
fibrosi
regress
hepat
c
respond
interferonribavirin
treatment
addit
novel
drug
could
develop
interfer
specif
develop
fibrosi
multipl
point
profibrot
signal
could
potenti
block
candid
compound
review
elsewher
control
trial
plan
least
one
compound
cuzn
superoxid
dismutas
initi
patient
nonrespond
interferon
recruit
potenti
studi
combin
interferonantifibrot
therapi
obviou
thu
inhibit
fibrosi
within
liver
potenti
delay
progress
cirrhosi
trigger
hbv
hcv
despit
